NEW HAVEN, Conn.--CuraGen and Genentech announced that their drug research collaboration will continue for at least two-and-a-half-years. The deal, struck up in 1997, applies CuraGen's high-throughput functional genomic technologies and disease expertise to discovery of protein therapeutics and antibodies.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.